BLUHM CARDIOVASCULAR INSTITUTE
We Can Help with Amyloidosis
The Northwestern Medicine Amyloid Program is among the largest comprehensive amyloid programs in the United States and world. Northwestern Medicine patients have access to the latest diagnostic tests, innovative treatments and leading-edge clinical trials for the treatment of all types of amyloidosis. Through the integration of medicine and research, our patient-focused, multidisciplinary team works together to design the best course of treatment for every patient.
LEARN MORE
312.NM.HEART (312.664.3278) | heart.nm.org | Inquiries: BCVI_info@nm.org
All Rights Reserved. ©2025 by Northwestern Medicine® and Northwestern Memorial HealthCare
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University.
Northwestern Medicine® | 251 East Huron Street | Chicago, Illinois 60611 | nm.org
Have you or a family member been diagnosed with amyloidosis?
Amyloidosis is a complex disease in which an amyloid protein builds up in the body and is deposited in tissues where it isn’t supposed to be. The amyloid protein, depending upon the type, is produced in the bone marrow or by the liver and can distribute within different organs, tissues and nerves. As the amount of amyloid protein increases and is deposited in these areas, health problems and organ damage may occur. Treatment options, including innovative drug therapies, are available to help manage symptoms and restrain the body’s production of the amyloid protein.
The treatment of amyloidosis has dramatically improved in the last decade. This evolution is primarily due to the rapid progression and development of new drug therapies. Ongoing clinical trials continue to advance treatment options, improving the outlook and survival associated with this disease.
Due to the various types of amyloidosis, treatment options will be unique to each patient. Treatment options are dependent on what type of amyloid protein is produced and the parts of the body affected.
Treatment options may include:
- Medications to address symptoms associated with nerve damage, heart failure and/or kidney failure.
- Well-tolerated chemotherapy drugs to suppress cells in the bone marrow
- Organ transplantation that may include heart, liver, or heart and liver
Meet the Amyloidosis Team
Northwestern Medicine Bluhm Cardiovascular Institute is a nationally recognized destination for those who require highly specialized heart and vascular care.
Northwestern Memorial Hospital is ranked as a top ten program in the nation (No. 7) for cardiology, heart & vascular surgery by U.S. News & World Report, 2024 - 2025. Our impressive U.S. News & World Report achievements are a reflection of the expert care provided and why patients choose to get their heart and vascular seconds opinions from Northwestern Medicine.
- Highest ranked cardiology, heart & vascular surgery program in Illinois for 17 consecutive years
- Highest available cardiology, heart & vascular surgery patient survival score since the metric was introduced
- Rated “High Performing” (the highest rating possible) for abdominal aortic aneurysm repair, aortic valve surgery, heart attack, heart failure and transcatheter aortic valve replacement (TAVR)
Make an Appointment
Whether you are experiencing symptoms that you do not understand or have already been diagnosed with amyloidosis and are looking for a second opinion, Northwestern Medicine Bluhm Cardiovascular Institute offers comprehensive expertise to you and your loved ones at multiple convenient locations.
Have a Nurse Contact Me
Fill out the form to have a nurse specializing in amyloidosis contact you by phone or email.
Amyloidosis Clinical Trial Options
Researchers at Northwestern Medicine conduct clinical trials that provide access to innovative therapies for the treatment of heart and vascular disease. Participating in a clinical trial is an opportunity to evaluate the effectiveness and safety of medications or study devices. The treatments used in the following clinical trials are investigational (experimental), which means they are not approved for commercial use by the U.S. FDA.
ATTR CM: Enrolling patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy. Eligible participants will be randomized to receive an investigational medicine, AKCEA-TTR-LRx, or placebo. Study drug or placebo will be administered by subcutaneous injections every 4 weeks. Participants in both groups will also receive daily supplemental doses of the recommended daily allowance of vitamin A and remain on current standard of care.
Bluhm Cardiovascular Institute
at Northwestern Memorial Hospital
675 N. Saint Clair Street
Galter Pavilion, Suite 19-100
Chicago, IL 60611
312.NM.HEART (312.664.3278) (TTY: 711)
Amyloidosis Clinical Trial Options
Researchers at Northwestern Medicine conduct clinical trials that provide access to innovative therapies for the treatment of heart and vascular disease. Participating in a clinical trial is an opportunity to evaluate the effectiveness and safety of medications or study devices. The study devices and delivery systems used in the following clinical trials are investigational (experimental), which means they are not approved for commercial use by the U.S. FDA.
MAGNITUDE: This phase 3, randomized, placebo-controlled study aims to evaluate the efficacy and safety of NTLA-2001 in participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM). NTLA-2001, an investigational CRISPR/Cas9 based genome editing therapy, is intended to edit TTR in hepatocytes so the gene stops making the TTR protein. Eligible participants will be randomized in a 2:1 ratio to receive a single infusion of NTLA-2001 or placebo. All participants will be followed for a minimum of 18 months. At completion of the study, participants that received NTLA-2001 will be asked to enroll in a 15 year long-term follow-up study.
DepleTTR-CM: The purpose of this phase 3, randomized, placebo-controlled study is to determine if the investigational drug, ALXN2220, is safe and effective to treat adult participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM). ALXN2220 is intended to promote the elimination of amyloid TTR (ATTR) deposits. Eligible participants will be randomized in a 2:1 ratio to receive study drug or matching placebo administered via IV infusion approximately every 4 weeks. All participants will be followed for a up to 48 months.